The Influence of Systemic Inflammation Response Index on Survival Outcomes of Limited-Stage Small-Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy.
Journal
Journal of oncology
ISSN: 1687-8450
Titre abrégé: J Oncol
Pays: Egypt
ID NLM: 101496537
Informations de publication
Date de publication:
2020
2020
Historique:
received:
31
07
2020
revised:
04
12
2020
accepted:
08
12
2020
entrez:
31
12
2020
pubmed:
1
1
2021
medline:
1
1
2021
Statut:
epublish
Résumé
Recent studies have indicated that the systemic inflammation response index (SIRI) can efficiently predict survival outcomes in various tumor types. Thusly, in absence of comparable investigations in limited-stage small-cell lung cancers (LS-SCLCs), we aimed to retrospectively evaluate the prognostic utility of SIRI in LS-SCLC patients treated with concurrent chemoradiotherapy (CRT). Search for the availability of an ideal SIRI cutoff that may stratify the entire patients' population into two particular groups with distinctive OS outcomes identified the 1.93 value (area under the curve (AUC): 72.9%; sensitivity: 74.6%; specificity: 70.1%): Group 1: SIRI <1.93 ( The results of this retrospective multi-institutional cohort analysis suggested that a pre-CRT SIRI was a strong and independent prognostic biomarker that reliably stratified LS-SCLC patients into two cohorts with significantly different OS outcomes.
Sections du résumé
BACKGROUND
BACKGROUND
Recent studies have indicated that the systemic inflammation response index (SIRI) can efficiently predict survival outcomes in various tumor types. Thusly, in absence of comparable investigations in limited-stage small-cell lung cancers (LS-SCLCs), we aimed to retrospectively evaluate the prognostic utility of SIRI in LS-SCLC patients treated with concurrent chemoradiotherapy (CRT).
RESULTS
RESULTS
Search for the availability of an ideal SIRI cutoff that may stratify the entire patients' population into two particular groups with distinctive OS outcomes identified the 1.93 value (area under the curve (AUC): 72.9%; sensitivity: 74.6%; specificity: 70.1%): Group 1: SIRI <1.93 (
CONCLUSIONS
CONCLUSIONS
The results of this retrospective multi-institutional cohort analysis suggested that a pre-CRT SIRI was a strong and independent prognostic biomarker that reliably stratified LS-SCLC patients into two cohorts with significantly different OS outcomes.
Identifiants
pubmed: 33381177
doi: 10.1155/2020/8832145
pmc: PMC7759417
doi:
Types de publication
Journal Article
Langues
eng
Pagination
8832145Informations de copyright
Copyright © 2020 Ahmet Kucuk et al.
Déclaration de conflit d'intérêts
The authors have declared that no conflicts of interest exist.
Références
Lancet Oncol. 2017 Aug;18(8):1116-1125
pubmed: 28642008
Cancer Treat Rep. 1981 Mar-Apr;65(3-4):187-95
pubmed: 6263468
Cancer Manag Res. 2019 Jan 18;11:909-919
pubmed: 30697081
J Clin Oncol. 1996 Mar;14(3):806-13
pubmed: 8622028
Cancer Res. 1986 Aug;46(8):4189-94
pubmed: 3015384
Oncotarget. 2016 May 3;7(18):26916-24
pubmed: 27029035
Nat Rev Cancer. 2017 Dec;17(12):725-737
pubmed: 29077690
J Clin Oncol. 2006 Oct 1;24(28):4539-44
pubmed: 17008692
Cancer. 2016 Jul 15;122(14):2158-67
pubmed: 27152949
J Thorac Oncol. 2016 Jan;11(1):39-51
pubmed: 26762738
Int Immunopharmacol. 2018 Dec;65:503-510
pubmed: 30408627
Cancer Manag Res. 2018 Nov 30;10:6563-6569
pubmed: 30555261
Oncotarget. 2017 Jun 29;8(43):75381-75388
pubmed: 29088873
PLoS One. 2016 Oct 5;11(10):e0164056
pubmed: 27706243
Curr Probl Cancer. 2020 Aug;44(4):100560
pubmed: 32122667
N Engl J Med. 1999 Aug 12;341(7):476-84
pubmed: 10441603
Oncotarget. 2017 May 23;8(21):34954-34960
pubmed: 28430597
Head Neck. 2020 Feb;42(2):336-343
pubmed: 31750591
Oncotarget. 2017 Jun 6;8(23):37200-37207
pubmed: 28380461
Cell Biochem Biophys. 2014 Jul;69(3):633-40
pubmed: 24554485
J Cancer Res Clin Oncol. 2017 Dec;143(12):2455-2468
pubmed: 28828692
N Engl J Med. 1999 Jan 28;340(4):265-71
pubmed: 9920950
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Clin Respir J. 2018 Sep;12(9):2433-2440
pubmed: 30074685
Tohoku J Exp Med. 2015;236(4):297-304
pubmed: 26250537
Ann Transl Med. 2019 Oct;7(20):572
pubmed: 31807553
Chemotherapy. 2019;64(3):129-137
pubmed: 31622969
Lancet. 2011 Nov 12;378(9804):1741-55
pubmed: 21565397
Crit Rev Oncol Hematol. 2014 Sep;91(3):257-70
pubmed: 24767978
Adv Ther. 2020 Aug;37(8):3606-3618
pubmed: 32642965
Lung. 2020 Apr;198(2):405-414
pubmed: 32016563
Sci Rep. 2015 Jun 18;5:10481
pubmed: 26084991
Int J Cancer. 1987 Feb 15;39(2):146-9
pubmed: 3026969
Future Oncol. 2019 Oct;15(29):3367-3379
pubmed: 31424272
J Cancer. 2018 Sep 7;9(18):3295-3302
pubmed: 30271489
J Clin Oncol. 1990 Sep;8(9):1563-74
pubmed: 2167954
Clin Lung Cancer. 2015 Nov;16(6):e165-71
pubmed: 25922292
Nature. 2008 Jul 24;454(7203):436-44
pubmed: 18650914
J Investig Med. 2019 Mar;67(3):691-698
pubmed: 30127099
Transl Lung Cancer Res. 2020 Aug;9(4):1169-1179
pubmed: 32953495
Clin Lung Cancer. 2019 Mar;20(2):117-123
pubmed: 30611672
J Clin Oncol. 1986 Sep;4(9):1307-13
pubmed: 3018182
Crit Rev Oncol Hematol. 2018 Mar;123:42-51
pubmed: 29482778
Lung Cancer. 2003 Mar;39(3):303-13
pubmed: 12609569